On the contrary, patients with LS and germline MLH1 or MSH2 mutations in genetic testing had a higher lifetime incidence of LS-related malignant disease than patients with LS and germline MSH6 or PSM2mutations [7]. This evidence concerns the gene MSH6 and Leigh syndrome.